Edition:
United Kingdom

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

216.55USD
15 Dec 2017
Change (% chg)

$5.70 (+2.70%)
Prev Close
$210.85
Open
$213.64
Day's High
$216.64
Day's Low
$210.19
Volume
1,041,035
Avg. Vol
308,300
52-wk High
$230.63
52-wk Low
$126.16

Chart for

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $29,871.53
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 168.71 16.44
EPS (TTM): -- -- --
ROI: -- 9.50 10.62
ROE: -- 14.87 14.20

BRIEF-Disney Board Elects Oracle And Illumina CEOs As Directors

* DISNEY BOARD ELECTS ORACLE’S SAFRA CATZ AND ILLUMINA’S FRANCIS A. DESOUZA AS DIRECTORS

07 Dec 2017

BRIEF-Illumina wins infringement suit against Premaitha Health and Ariosa Diagnostics

* Illumina wins infringement suit against Premaitha Health and Ariosa Diagnostics

21 Nov 2017

BRIEF-Illumina announces ‍introduction of its NextSeq 550Dx instrument

* Illumina Inc - ‍introduction of its NextSeq 550Dx instrument, co's second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system​

15 Nov 2017

BRIEF-Illumina reports Q3 GAAP earnings per share $1.11

* Illumina reports financial results for third quarter of fiscal year 2017

24 Oct 2017

BRIEF-Illumina files new patent infringement suit against Premaitha Health Plc

* Illumina Inc - ‍filed new patent infringement suit against Premaitha Health Plc in High Court of Justice, Chancery Division, Patents Court in UK Source text for Eikon: Further company coverage:

07 Sep 2017

'Liquid biopsy' spots early-stage cancers in blood: U.S. study

CHICAGO A test that scans blood for tumor-specific DNA identified early-stage cancer in more than half of 138 patients with the disease, U.S. researchers reported on Wednesday, marking a new milestone in the rush for so-called "liquid biopsies."

16 Aug 2017

'Liquid biopsy' spots early-stage cancers in blood -U.S. study

CHICAGO, Aug 16 A test that scans blood for tumor-specific DNA identified early-stage cancer in more than half of 138 patients with the disease, U.S. researchers reported on Wednesday, marking a new milestone in the rush for so-called "liquid biopsies."

16 Aug 2017

Illumina shares sparkle on strong demand for new gene tech

Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

02 Aug 2017

CORRECTED-UPDATE 1-Illumina shares sparkle on strong demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

02 Aug 2017

Illumina shares sparkle on demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 12 percent on Wednesday, a day after the company raised its full-year revenue forecast on higher-than-expected demand for its new gene-sequencing technology.

02 Aug 2017

Earnings vs. Estimates